+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Postpartum Depression Drugs Market Size, Share & Trends Analysis Report by Type (Postpartum Blues, Anxiety, PTSD), Treatment (Pharmacotherapy, Hormonal Therapy), Route of Administration, Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 120 Pages
  • June 2024
  • Region: Global
  • Grand View Research
  • ID: 5983008
The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Postpartum Depression Drugs Market Report Highlights

  • The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
  • Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period. This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
  • In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
  • The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
  • North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Treatment
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Treatment and Treatment outlook
2.2.2. Route of Administration outlook
2.2.3. Distribution Channel and Availability outlook
2.2.4. Regional outlook
2.3. Competitive Insights
Chapter 3. Postpartum Depression Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of postpartum depression
3.2.1.2. Advancements in drug development
3.2.1.3. Growing awareness and diagnosis
3.2.2. Market restraint analysis
3.2.2.1. High cost of treatment
3.2.2.2. Regulatory challenges for new drug approvals
3.3. Postpartum Depression Drugs Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
3.3.3. Pipeline Analysis
Chapter 4. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis
4.1. Global Postpartum Depression Drugs Market: Type Dashboard
4.2. Global Postpartum Depression Drugs Market: Type Movement Analysis
4.3. Global Postpartum Depression Drugs Market by Treatment, Revenue
4.4. Postpartum Blues
4.4.1. Postpartum blues market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Postpartum Anxiety
4.5.1. Postpartum anxiety market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Postpartum Obsessive-Compulsive Disorder (OCD)
4.6.1. Postpartum obsessive-compulsive disorder (OCD) market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Postpartum Post-Traumatic Stress Disorder (PTSD)
4.7.1. Postpartum post-traumatic stress disorder (PTSD) market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Postpartum Panic Disorder
4.8.1. Postpartum panic disorder market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Preventive
4.9.1. Postpartum psychosis market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Postpartum Depression Drugs Market: Treatment Estimates & Trend Analysis
5.1. Global Postpartum Depression Drugs Market: Treatment Dashboard
5.2. Global Postpartum Depression Drugs Market: Treatment Movement Analysis
5.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, By Treatment, Revenue (USD Million)
5.4. Pharmacotherapy
5.4.1. Pharmacotherapy market estimates and forecasts 2018 to 2030 (USD Million)
5.5. Hormonal Therapy
5.5.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Postpartum Depression Drugs Market: Route of Administration Estimates & Trend Analysis
6.1. Global Postpartum Depression Drugs Market: Route of Administration Dashboard
6.2. Global Postpartum Depression Drugs Market: Route of Administration Movement Analysis
6.3. Global Postpartum Depression Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
6.4. Parenteral
6.4.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Oral
6.5.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Postpartum Depression Drugs Market: Distribution Channel Estimates & Trend Analysis
7.1. Global Postpartum Depression Drugs Market: Distribution Channel Dashboard
7.2. Global Postpartum Depression Drugs Market: Distribution Channel Movement Analysis
7.3. Global Postpartum Depression Drugs Market Estimates and Forecasts by Distribution Channel, Revenue (USD Million)
7.4. Hospital Pharmacy
7.4.1. Hospital pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
7.5. Retail Pharmacy
7.5.1. Retail pharmacy market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Others (Online Pharmacy)
7.6.1. Others (online pharmacy) market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Postpartum Depression Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration
8.1. Regional Dashboard
8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
8.3. North America
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Regulatory framework/ reimbursement structure
8.3.1.3. Competitive scenario
8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.3.2. Canada
8.3.2.1. Key country dynamics
8.3.2.2. Regulatory framework/ reimbursement structure
8.3.2.3. Competitive scenario
8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.3.3. Mexico
8.3.3.1. Key country dynamics
8.3.3.2. Regulatory framework/ reimbursement structure
8.3.3.3. Competitive scenario
8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.4. Europe
8.4.1. UK
8.4.1.1. Key country dynamics
8.4.1.2. Regulatory framework/ reimbursement structure
8.4.1.3. Competitive scenario
8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.4.2. Germany
8.4.2.1. Key country dynamics
8.4.2.2. Regulatory framework/ reimbursement structure
8.4.2.3. Competitive scenario
8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.4.3. France
8.4.3.1. Key country dynamics
8.4.3.2. Regulatory framework/ reimbursement structure
8.4.3.3. Competitive scenario
8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.4.4. Italy
8.4.4.1. Key country dynamics
8.4.4.2. Regulatory framework/ reimbursement structure
8.4.4.3. Competitive scenario
8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.4.5. Spain
8.4.5.1. Key country dynamics
8.4.5.2. Regulatory framework/ reimbursement structure
8.4.5.3. Competitive scenario
8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.4.6. Norway
8.4.6.1. Key country dynamics
8.4.6.2. Regulatory framework/ reimbursement structure
8.4.6.3. Competitive scenario
8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.4.7. Sweden
8.4.7.1. Key country dynamics
8.4.7.2. Regulatory framework/ reimbursement structure
8.4.7.3. Competitive scenario
8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.4.8. Denmark
8.4.8.1. Key country dynamics
8.4.8.2. Regulatory framework/ reimbursement structure
8.4.8.3. Competitive scenario
8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.5. Asia Pacific
8.5.1. Japan
8.5.1.1. Key country dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.5.2. China
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. India
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework/ reimbursement structure
8.5.3.3. Competitive scenario
8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Australia
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework/ reimbursement structure
8.5.4.3. Competitive scenario
8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.5.5. South Korea
8.5.5.1. Key country dynamics
8.5.5.2. Regulatory framework/ reimbursement structure
8.5.5.3. Competitive scenario
8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.5.6. Thailand
8.5.6.1. Key country dynamics
8.5.6.2. Regulatory framework/ reimbursement structure
8.5.6.3. Competitive scenario
8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Latin America
8.6.1. Brazil
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.6.2. Argentina
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.7. MEA
8.7.1. South Africa
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.7.2. Saudi Arabia
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. UAE
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. Kuwait
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Company/Competition Categorization
9.2. Vendor Landscape
9.2.1. List of key distributors and channel partners
9.2.2. Key customers
9.2.3. Key company market share analysis, 2023
9.2.4. Sage Therapeutics, Inc.
9.2.4.1. Company overview
9.2.4.2. Financial performance
9.2.4.3. Product benchmarking
9.2.4.4. Strategic initiatives
9.2.5. Pfizer Inc.
9.2.5.1. Company overview
9.2.5.2. Financial performance
9.2.5.3. Product benchmarking
9.2.5.4. Strategic initiatives
9.2.6. Eli Lilly and Company.
9.2.6.1. Company overview
9.2.6.2. Financial performance
9.2.6.3. Product benchmarking
9.2.6.4. Strategic initiatives
9.2.7. GSK plc
9.2.7.1. Company overview
9.2.7.2. Financial performance
9.2.7.3. Product benchmarking
9.2.7.4. Strategic initiatives
9.2.8. Merck & Co., Inc.
9.2.8.1. Company overview
9.2.8.2. Financial performance
9.2.8.3. Product benchmarking
9.2.8.4. Strategic initiatives
9.2.9. Biogen Inc.
9.2.9.1. Company overview
9.2.9.2. Financial performance
9.2.9.3. Product benchmarking
9.2.9.4. Strategic initiatives
9.2.10. Bausch Health Companies Inc.
9.2.10.1. Company overview
9.2.10.2. Financial performance
9.2.10.3. Product benchmarking
9.2.10.4. Strategic initiatives
9.2.11. Cipla Inc.
9.2.11.1. Company overview
9.2.11.2. Financial performance
9.2.11.3. Product benchmarking
9.2.11.4. Strategic initiatives
9.2.12. Novartis AG.
9.2.12.1. Company overview
9.2.12.2. Financial performance
9.2.12.3. Product benchmarking
9.2.12.4. Strategic initiatives
9.2.13. Teva Pharmaceutical Industries Ltd.
9.2.13.1. Company overview
9.2.13.2. Financial performance
9.2.13.3. Product benchmarking
9.2.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America postpartum depression drugs market, by region, 2018-2030 (USD Million)
Table 3 North America postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 4 North America postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 5 North America postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 6 North America postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 7 U.S. postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 8 U.S. postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 9 U.S. postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 10 U.S. postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 11 Canada postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 12 Canada postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 13 Canada postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 14 Canada postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 15 Mexico postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 16 Mexico postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 17 Mexico postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 18 Mexico postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 19 Europe postpartum depression drugs market, by region, 2018-2030 (USD Million)
Table 20 Europe postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 21 Europe postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 22 Europe postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 23 Europe postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 24 Germany postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 25 Germany postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 26 Germany postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 27 Germany postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 28 UK postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 29 UK postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 30 UK postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 31 UK postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 32 France postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 33 France postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 34 France postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 35 France postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 36 Italy postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 37 Italy postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 38 Italy postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 39 Italy postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 40 Spain postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 41 Spain postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 42 Spain postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 43 Spain postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 44 Denmark postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 45 Denmark postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 46 Denmark postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 47 Denmark postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 48 Sweden postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 49 Sweden postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 50 Sweden postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 51 Sweden postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 52 Norway postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 53 Norway postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 54 Norway postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 55 Norway postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 56 Asia Pacific postpartum depression drugs market, by region, 2018-2030 (USD Million)
Table 57 Asia Pacific postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 58 Asia Pacific postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 59 Aisa Pacific postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 60 Asia Pacific postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 61 China postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 62 China postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 63 China postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 64 China postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 65 Japan postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 66 Japan postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 67 Japan postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 68 Japan postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 69 India postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 70 India postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 71 India postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 72 India postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 73 South Korea postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 74 South Korea postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 75 South Korea postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 76 South Korea postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 77 Australia postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 78 Australia postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 79 Australia postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 80 Australia postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 81 Thailand postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 82 Thailand postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 83 Thailand postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 84 Thailand postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 85 Latin America postpartum depression drugs market, by region, 2018-2030 (USD Million)
Table 86 Latin America postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 87 Latin America postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 88 Latin America postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 89 Latin America postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 90 Brazil postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 91 Brazil postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 92 Brazil postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 93 Brazil postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 94 Argentina postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 95 Argentina postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 96 Argentina postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 97 Argentina postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 98 MEA postpartum depression drugs market, by region, 2018-2030 (USD Million)
Table 99 MEA postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 100 MEA postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 101 MEA postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 102 MEA postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 103 South Africa postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 104 South Africa postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 105 South Africa postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 106 South Africa postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 107 Saudi Arabia postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 108 Saudi Arabia postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 109 Saudi Arabia postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 110 Saudi Arabia postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 111 UAE postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 112 UAE postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 113 UAE postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 114 UAE postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
Table 115 Kuwait postpartum depression drugs market, by type, 2018-2030 (USD Million)
Table 116 Kuwait postpartum depression drugs market, by treatment, 2018-2030 (USD Million)
Table 117 Kuwait postpartum depression drugs market, by route of administration, 2018-2030 (USD Million)
Table 118 Kuwait postpartum depression drugs market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews in North America
Figure 5 Primary interviews in Europe
Figure 6 Primary interviews in APAC
Figure 7 Primary interviews in Latin America
Figure 8 Primary interviews in MEA
Figure 9 Market research approaches
Figure 10 Value-chain-based sizing & forecasting
Figure 11 QFD modeling for market share assessment
Figure 12 Market formulation & validation
Figure 13 Postpartum depression drugs market: market outlook
Figure 14 Postpartum depression drugs competitive insights
Figure 15 Parent market outlook
Figure 16 Related/ancillary market outlook
Figure 17 Postpartum depression drugs market driver impact
Figure 18 Postpartum depression drugs market restraint impact
Figure 19 Postpartum depression drugs market: Type movement analysis
Figure 20 Postpartum depression drugs market: Type outlook and key takeaways
Figure 21 Postpartum blues market estimates and forecast, 2018-2030 (USD Million)
Figure 22 Postpartum anxiety market estimates and forecast, 2018-2030 (USD Million)
Figure 23 Postpartum obsessive-compulsive disorder (OCD) market estimates and forecast, 2018-2030 (USD Million)
Figure 24 Postpartum post-traumatic stress disorder (PTSD) market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Postpartum panic disorder market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Postpartum psychosis market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Postpartum depression drugs market: Treatment movement analysis
Figure 28 Postpartum depression drugs market: Treatment outlook and key takeaways
Figure 29 Pharmacotherapy market estimates and forecast, 2018-2030 (USD Million)
Figure 30 Hormonal therapy market estimates and forecast, 2018-2030 (USD Million)
Figure 31 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 32 Postpartum depression drugs market: Route of administration movement analysis
Figure 33 Postpartum depression drugs market: Route of administration outlook and key takeaways
Figure 34 Parenteral market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Oral market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Others market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Postpartum depression drugs market: Distribution Channel movement analysis
Figure 38 Postpartum depression drugs market: Distribution Channel outlook and key takeaways
Figure 39 Hospital pharmacy market estimates and forecast, 2018-2030 (USD Million)
Figure 40 Retail pharmacy market estimates and forecast, 2018-2030 (USD Million)
Figure 41 Others (online pharmacy) market estimates and forecast, 2018-2030 (USD Million)
Figure 42 Global Postpartum Depression Drugs market: Regional movement analysis
Figure 43 Global Postpartum Depression Drugs market: Regional outlook and key takeaways
Figure 44 Global Postpartum Depression Drugs market share and leading players
Figure 45 North America, by country
Figure 46 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 U.S. key country dynamics
Figure 48 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Canada key country dynamics
Figure 50 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Mexico key country dynamics
Figure 52 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 UK key country dynamics
Figure 55 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 Germany key country dynamics
Figure 57 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 France key country dynamics
Figure 59 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 Italy key country dynamics
Figure 61 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 62 Spain key country dynamics
Figure 63 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Denmark key country dynamics
Figure 65 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 66 Sweden key country dynamics
Figure 67 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 68 Norway key country dynamics
Figure 69 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 70 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 71 China key country dynamics
Figure 72 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 73 Japan key country dynamics
Figure 74 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 75 India key country dynamics
Figure 76 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 77 Thailand key country dynamics
Figure 78 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 79 South Korea key country dynamics
Figure 80 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 81 Australia key country dynamics
Figure 82 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 83 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 84 Brazil key country dynamics
Figure 85 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 86 Argentina key country dynamics
Figure 87 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 88 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 89 South Africa key country dynamics
Figure 90 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 91 Saudi Arabia key country dynamics
Figure 92 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 93 UAE key country dynamics
Figure 94 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 95 Kuwait key country dynamics
Figure 96 Kuwait market estimates and forecasts, 2018-2030 (USD Million)
Figure 97 Market share of key market players- postpartum depression drugs market

Companies Mentioned

  • Sage Therapeutics, Inc.
  • Pfizer Inc.
  • Eli Lilly and Company.
  • GSK plc
  • Merck & Co., Inc.
  • Biogen Inc.
  • Bausch Health Companies Inc.
  • Cipla Inc.
  • Novartis AG.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information